These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 36645632)
41. Pre-treatment with angiotensin-(1-7) inhibits tumor growth via autophagy by downregulating PI3K/Akt/mTOR signaling in human nasopharyngeal carcinoma xenografts. Lin YT; Wang HC; Chuang HC; Hsu YC; Yang MY; Chien CY J Mol Med (Berl); 2018 Dec; 96(12):1407-1418. PubMed ID: 30374682 [TBL] [Abstract][Full Text] [Related]
42. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress. Li Q; Ni W; Deng Z; Liu M; She L; Xie Q Fundam Clin Pharmacol; 2017 Jun; 31(3):301-310. PubMed ID: 28078787 [TBL] [Abstract][Full Text] [Related]
43. Synergistic effects of autophagy inhibitors combined with cisplatin against cisplatin-resistant nasopharyngeal cancer cells. Yin W; Xu J; Mao Y Biochem Cell Biol; 2021 Jun; 99(3):322-329. PubMed ID: 34038188 [TBL] [Abstract][Full Text] [Related]
44. Integrin α5 mediates intrinsic cisplatin resistance in three-dimensional nasopharyngeal carcinoma spheroids via the inhibition of phosphorylated ERK /caspase-3 induced apoptosis. Ngaokrajang U; Janvilisri T; Sae-Ueng U; Prungsak A; Kiatwuthinon P Exp Cell Res; 2021 Sep; 406(2):112765. PubMed ID: 34358523 [TBL] [Abstract][Full Text] [Related]
45. ENOX2 inhibition enhances infiltration of effector memory T-cell and mediates response to chemotherapy in immune-quiescent nasopharyngeal carcinoma. Kam NW; Laczka O; Li X; Wilkinson J; Hung D; Lai SPH; Wu KC; Tsao SW; Dai W; Che CM; Lee VH; Kwong DL J Adv Res; 2024 Feb; 56():69-86. PubMed ID: 37061217 [TBL] [Abstract][Full Text] [Related]
46. Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling. Hu WJ; Liu J; Zhong LK; Wang J Biomed Pharmacother; 2018 Jun; 102():681-688. PubMed ID: 29604587 [TBL] [Abstract][Full Text] [Related]
47. Effects of Cisplatin Combined with Metformin on Proliferation and Apoptosis of Nasopharyngeal Carcinoma Cells. Shi L; Mei Y; Duan X; Wang B Comput Math Methods Med; 2022; 2022():2056247. PubMed ID: 35422875 [TBL] [Abstract][Full Text] [Related]
48. Jervine exhibits anticancer effects on nasopharyngeal carcinoma through promoting autophagic apoptosis via the blockage of Hedgehog signaling. Chen J; Wen B; Wang Y; Wu S; Zhang X; Gu Y; Wang Z; Wang J; Zhang W; Yong J Biomed Pharmacother; 2020 Dec; 132():110898. PubMed ID: 33113432 [TBL] [Abstract][Full Text] [Related]
49. Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells. Low SY; Tan BS; Choo HL; Tiong KH; Khoo AS; Leong CO Cancer Lett; 2012 Jan; 314(2):166-75. PubMed ID: 22033244 [TBL] [Abstract][Full Text] [Related]
50. Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies. Noh YH; Lim HS; Jung JA; Song TH; Bae KS Cancer Chemother Pharmacol; 2015 Jan; 75(1):97-109. PubMed ID: 25377158 [TBL] [Abstract][Full Text] [Related]
51. Autophagy related 4B, upregulated by HIF-1α, attenuates the sensitivity to cisplatin in nasopharyngeal carcinoma cells. Huang J; Li HB; Yu S; Yuan F; Lou ZP Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4793-4802. PubMed ID: 32432742 [TBL] [Abstract][Full Text] [Related]
52. Parallel genome-wide RNAi screens identify lymphocyte-specific protein tyrosine kinase (LCK) as a targetable vulnerability of cell proliferation and chemoresistance in nasopharyngeal carcinoma. Liew K; Yu GQS; Wei Pua LJ; Wong LZ; Tham SY; Hii LW; Lim WM; OuYong BM; Looi CK; Mai CW; Fei-Lei Chung F; Tan LP; Ahmad M; Soo-Beng Khoo A; Leong CO Cancer Lett; 2021 Apr; 504():81-90. PubMed ID: 33587980 [TBL] [Abstract][Full Text] [Related]
53. Loss of AKR1C1 is a good prognostic factor in advanced NPC cases and increases chemosensitivity to cisplatin in NPC cells. Zhou C; Shen G; Yang F; Duan J; Wu Z; Yang M; Liu Y; Du X; Zhang X; Xiao S J Cell Mol Med; 2020 Jun; 24(11):6438-6447. PubMed ID: 32307891 [TBL] [Abstract][Full Text] [Related]
54. The efficacy of cisplatin on nasopharyngeal carcinoma cells may be increased via the downregulation of fibroblast growth factor receptor 2. Pu L; Su L; Kang X Int J Mol Med; 2019 Jul; 44(1):57-66. PubMed ID: 31115494 [TBL] [Abstract][Full Text] [Related]
55. Isoprenylcysteine carboxylmethyltransferase is associated with nasopharyngeal carcinoma chemoresistance and Ras activation. Zhu Y; Hu Q; Li H Biochem Biophys Res Commun; 2019 Aug; 516(3):784-789. PubMed ID: 31253403 [TBL] [Abstract][Full Text] [Related]
56. Metabolite identification of a new tyrosine kinase inhibitor, HM781-36B, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry. Kim E; Kim H; Suh K; Kwon S; Lee G; Park NH; Hong J Rapid Commun Mass Spectrom; 2013 Jun; 27(11):1183-95. PubMed ID: 23650031 [TBL] [Abstract][Full Text] [Related]
57. Reversal of cisplatin sensitization and abrogation of cisplatin-enriched cancer stem cells in 5-8F nasopharyngeal carcinoma cell line through a suppression of Wnt/β-catenin-signaling pathway. Sinnung S; Janvilisri T; Kiatwuthinon P Mol Cell Biochem; 2021 Apr; 476(4):1663-1672. PubMed ID: 33423190 [TBL] [Abstract][Full Text] [Related]
58. [Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor gefitinib on nasopharyngeal carcinoma xenografts]. Wang SS; Guan ZZ; Xiang YQ; Jiang WQ; Lin TY; Zhang L Ai Zheng; 2004 Nov; 23(11 Suppl):1365-9. PubMed ID: 15566638 [TBL] [Abstract][Full Text] [Related]
59. Regorafenib inhibits growth, survival and angiogenesis in nasopharyngeal carcinoma and is synergistic with Mcl-1 inhibitor. Li J; Hua Q J Pharm Pharmacol; 2023 Sep; 75(9):1177-1185. PubMed ID: 37133348 [TBL] [Abstract][Full Text] [Related]
60. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis. Li N; Feng L; Han HQ; Yuan J; Qi XK; Lian YF; Kuang BH; Zhang YC; Deng CC; Zhang HJ; Yao YY; Xu M; He GP; Zhao BC; Gao L; Feng QS; Chen LZ; Yang L; Yang D; Zeng YX Cancer Lett; 2016 Oct; 381(1):14-22. PubMed ID: 27424523 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]